AXGT:NSD-Sio Gene Therapies, Inc (USD)

COMMON STOCK | Biotechnology | NSD

Last Closing Price

USD 2.56

Change

0.00 (0.00)%

Market Cap

USD 0.10B

Volume

1.54M

Average Target Price

N/A
Average Analyst Rating

N/A

Fundamental Analysis

Verdict

About

Axovant Gene Therapies Ltd., a clinical-stage gene therapy company, focuses on developing various product candidates for debilitating neurodegenerative diseases. The company's clinical-stage programs include AXO-Lenti-PD program for the treatment of Parkinson's disease; AXO-AAV-GM1 program for the treatment of GM1 gangliosidosis; and AXO-AAV-GM2 program for the treatment of GM2 gangliosidosis. It has a license agreement with Oxford BioMedica (UK) Ltd. and The University of Massachusetts Medical School. The company was formerly known as Axovant Sciences Ltd. and changed its name to Axovant Gene Therapies Ltd. in March 2019. Axovant Gene Therapies Ltd. was founded in 2014 and is based in London, the United Kingdom. Address: 11-12 St. James's Square, London, United Kingdom, SW1Y 4LB

Company Website : http://www.axovant.com

Address : 11-12 St. James's Square, London, United Kingdom, SW1Y 4LB

Employees : 38

Fiscal Year End : March

Currency: USD

Country : USA

Technical Indicators

Beta : 1.58

52 Week High : 5.74

Short Ratio : 0.65

52 Week Low : 1.41

Shorted Shares : 1,440,108

200 Day Moving Average : 3.10

Shorted Shares Previous Month : 526,502

50 Day Moving Average : 2.84

Shares Held By Insiders : 395.71%

Short Percentage : 4.00%

Shares Held by Institutions : 24.27%

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2021-03-03 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
MRNA Moderna, Inc

-15.59 (-10.62%)

 USD58.69B N/A N/A
VRTX Vertex Pharmaceuticals Incorpo..

-3.62 (-1.71%)

 USD55.13B 20.61 15.08
REGN Regeneron Pharmaceuticals, Inc

-8.13 (-1.79%)

 USD48.73B 14.90 11.87
ALXN Alexion Pharmaceuticals, Inc

-2.18 (-1.45%)

 USD33.27B 55.63 33.22
BGNE BeiGene, Ltd

-1.91 (-0.62%)

 USD29.03B N/A N/A
RPRX Royalty Pharma plc

-3.38 (-7.20%)

 USD28.50B 22.60 14.17
SGEN Seagen Inc

-5.78 (-3.76%)

 USD27.85B 45.61 37.70
BNTX BioNTech SE

-7.73 (-7.36%)

 USD25.28B -99,999.99 N/A
GMAB Genmab A/S

-1.28 (-3.78%)

 USD22.05B 26.59 3.17
IMMU Immunomedics, Inc

N/A

 USD20.31B N/A N/A

ETFs Containing AXGT

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Biotechnology)		 Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -7.91% N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return -7.91% N/A N/A N/A N/A
Trailing 12 Months  
Capital Gain -14.95% N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return -14.95% N/A N/A N/A N/A
Trailing 5 Years  
Capital Gain -97.37% N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return -97.37% N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain -24.51% 11% F 5% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -24.51% 11% F 5% F
Risk Return Profile  
Volatility (Standard Deviation) 28.72% 86% B 52% F
Risk Adjusted Return -85.34% 8% F 4% F
Market Capitalization 0.10B N/A N/A N/A N/A
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Biotechnology)		 Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio N/A N/A N/A N/A N/A
Price/Book Ratio 1.73 N/A N/A N/A N/A
Price / Cash Flow Ratio -1.47 N/A N/A N/A N/A
EV/EBITDA N/A N/A N/A N/A N/A
Management Effectiveness  
Return on Equity N/A N/A N/A N/A N/A
Return on Invested Capital -78.49% N/A N/A N/A N/A
Return on Assets -37.29% N/A N/A N/A N/A
Debt to Equity Ratio N/A N/A N/A N/A N/A
Technical Ratios  
Short Ratio 0.65 N/A N/A N/A N/A
Short Percent 6.72% N/A N/A N/A N/A
Beta 1.58 N/A N/A N/A N/A
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Low volatility

The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.